cas 50591-22-5|| where to buy 1-Methyl-1H-benzimidazol-5-ol

Nom du produit:1-Methyl-1H-benzimidazol-5-ol

IUPAC Name:1-methyl-1H-1,3-benzodiazol-5-ol

Unité d'emballage	Stock disponible	Prix($)
CM154913-5g	in stock	ƥǪ
CM154913-10g	in stock	ƈľǪ
CM154913-25g	in stock	Ǚŗƥ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 50591-22-5 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:50591-22-5; Formule moléculaire:C8H8N2O; Point de fusion:-; Code SMILES:OC1=CC=C2N(C)C=NC2=C1; Densité:

: Numéro de catalogue:CM154913; Poids moléculaire:148.17; Point d'ébullition:337.7±34.0°C at 760 mmHg; N° Mdl:MFCD00456136; Stockage:Store at 2-8°C.

: Benzimidazoles; Benzimidazole is a benzo derivative of imidazole. It is a kind of bicyclic aromatic organic compounds, which is formed by fusing a six-membered benzene ring and five-membered imidazole at positions 4 and 5 of imidazole ring. It is an important pharmacophore of many biologically active heterocyclic compounds with various pharmacological activities. Benzimidazoles and their derivatives have developed into dynamic heterocyclic systems due to their potency in a variety of biologically active compounds such as anticancer, bactericidal and antiviral drugs. Benzimidazoles are a class of therapeutic motifs with broad relevance in medicinal chemistry.

: Zongertinib; Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients.
Zongertinib (also known as BI 1810631) is an investigational oral HER2-specific tyrosine kinase inhibitor (TKI) that is being developed as a potential treatment for HER2 mutated non-small cell lung cancer (NSCLC). Zongertinib was granted FDA Fast Track Designation in 2023, then in 2024 it was granted Breakthrough Therapy Designation by the U.S. FDA and China CDE for the treatment of adult patients with advanced NSCLC whose tumors have activating HER2 mutations, and who have received a prior systemic therapy.